Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses

Vaccine

Volumn 30, Issue 18, 2012, Pages 2848-2858

  Rudilla, Francesc ^a   Fayolle, Catherine ^b,c   Casares, Noelia ^a   Durantez, Maika ^a   Arribillaga, Laura ^a   Lozano, Teresa ^a   Villanueva, Lorea ^a   Pio, Ruben ^a   Sarobe, Pablo ^a   Leclerc, Claude ^b,c   Prieto, Jesús ^a,d   Lasarte, Juan José ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b INSTITUT PASTEUR   (France)

^c INSERM   (France)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adjuvant; C5a; Dendritic cell; EDA; Fusion protein; Vaccine

Indexed keywords

CCL1 CHEMOKINE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; CXCL1 CHEMOKINE; EPITOPE; FIBRONECTIN; INTERLEUKIN 10; OVALBUMIN; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MIGRATION; CELL STIMULATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA IMMUNIZATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY;

ANAPHYLATOXINS; ANIMALS; CANCER VACCINES; COMPLEMENT C5A; CYTOKINES; ECTODYSPLASINS; EPITOPES, T-LYMPHOCYTE; FEMALE; MICE; MICE, INBRED C57BL; NEOPLASMS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 4; VACCINES, DNA;

EID: 84859009399     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.052     Document Type: Article

References (62)

1. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449(7161):419-426.
2. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006, 6(6):476-483.
3. Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001, 194(6):769-779.
4. Delneste Y., Magistrelli G., Gauchat J., Haeuw J., Aubry J., Nakamura K., et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002, 17(3):353-362.
5. He L.Z., Crocker A., Lee J., Mendoza-Ramirez J., Wang X.T., Vitale L.A., et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol 2007, 178(10):6259-6267.
6. Cuadros C., Lopez-Hernandez F.J., Dominguez A.L., McClelland M., Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 2004, 72(5):2810-2816.
7. Lasarte J.J., Casares N., Gorraiz M., Hervas-Stubbs S., Arribillaga L., Mansilla C., et al. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol 2007, 178(2):748-756.
8. LeibundGut-Landmann S., Gross O., Robinson M.J., Osorio F., Slack E.C., Tsoni S.V., et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007, 8(6):630-638.
9. Tighe H., Takabayashi K., Schwartz D., Marsden R., Beck L., Corbeil J., et al. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000, 30(7):1939-1947.
10. Ahonen C.L., Doxsee C.L., McGurran S.M., Riter T.R., Wade W.F., Barth R.J., et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004, 199(6):775-784.
11. Wen T., Bukczynski J., Watts T.H. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002, 168(10):4897-4906.
12. Ahlers J.D., Belyakov I.M., Berzofsky J.A. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med 2003, 3(3):285-301.
13. Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007, 171(3):715-727.
14. Beutler B., Hoebe K., Du X., Ulevitch R.J. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003, 74(4):479-485.
15. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449(7164):819-826.
16. Gerard C., Gerard N.P. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 1994, 12:775-808.
17. Guo R.F., Ward P.A. Role of C5a in inflammatory responses. Annu Rev Immunol 2005, 23:821-852.
18. Lahiri A., Das P., Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 2008, 26(52):6777-6783.
19. Floreani A.A., Gunselman S.J., Heires A.J., Hauke R.J., Tarantolo S., Jackson J.D. Novel C5a agonist-based dendritic cell vaccine in a murine model of melanoma. Cell Cycle 2007, 6(22):2835-2839.
20. Li K., Fazekasova H., Wang N., Peng Q., Sacks S.H., Lombardi G., et al. Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a. Immunobiology 2011.
21. Xu G.L., Zhang K.Q., Guo B., Zhao T.T., Yang F., Jiang M., et al. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant. Vaccine 2010, 28(44):7221-7227.
22. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33(4):492-503.
23. Guy B. The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 2007, 5(7):505-517.
24. Hajishengallis G., Lambris J.D. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol 2010, 31(4):154-163.
25. Zhang X., Kimura Y., Fang C., Zhou L., Sfyroera G., Lambris J.D., et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 2007, 110(1):228-236.
26. Hawlisch H., Belkaid Y., Baelder R., Hildeman D., Gerard C., Kohl J. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 2005, 22(4):415-426.
27. Kohl J. The role of complement in danger sensing and transmission. Immunol Res 2006, 34(2):157-176.
28. Mansilla C., Gorraiz M., Martinez M., Casares N., Arribillaga L., Rudilla F., et al. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. J Hepatol 2009, 51(3):520-527.
29. Mansilla C., Berraondo P., Durantez M., Martinez M., Casares N., Arribillaga L., et al. Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain A from fibronectin. Int J Cancer 2011.
30. Moore M.W., Carbone F.R., Bevan M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988, 54(6):777-785.
31. Corbett T.H., Griswold D.P., Roberts B.J., Peckham J.C., Schabel F.M. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975, 35(9):2434-2439.
32. Marincek B.C., Kuhnle M.C., Srokowski C., Schild H., Hammerling G., Momburg F. Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion. Mol Immunol 2008, 46(1):181-191.
33. Reis e Sousa C., Germain R.N. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J Exp Med 1995, 182(3):841-851.
34. Mouries J., Moron G., Schlecht G., Escriou N., Dadaglio G., Leclerc C. Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood 2008, 112(9):3713-3722.
35. Okamura Y., Watari M., Jerud E.S., Young D.W., Ishizaka S.T., Rose J., et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001, 276(13):10229-10233.
36. Durr C., Pfeifer D., Claus R., Schmitt-Graeff A., Gerlach U.V., Graeser R., et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res 2010, 70(24):10170-10181.
37. Hoelzinger D.B., Smith S.E., Mirza N., Dominguez A.L., Manrique S.Z., Lustgarten J. Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J Immunol 2010, 184(12):6833-6842.
38. Iellem A., Mariani M., Lang R., Recalde H., Panina-Bordignon P., Sinigaglia F., et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001, 194(6):847-853.
39. Nguyen K.D., Fohner A., Booker J.D., Dong C., Krensky A.M., Nadeau K.C. XCL1 enhances regulatory activities of CD4+ CD25(high) CD127(low/-) T cells in human allergic asthma. J Immunol 2008, 181(8):5386-5395.
40. Huang H., Dawicki W., Zhang X., Town J., Gordon J.R. Tolerogenic dendritic cells induce CD4+CD25hiFoxp3+ regulatory T cell differentiation from CD4+CD25-/loFoxp3- effector T cells. J Immunol 2010, 185(9):5003-5010.
41. Gasque P., Singhrao S.K., Neal J.W., Wang P., Sayah S., Fontaine M., et al. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 1998, 160(7):3543-3554.
42. Gerard N.P., Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991, 349(6310):614-617.
43. Wetsel R.A. Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 1995, 7(1):48-53.
44. He S., Cao Q., Yoneyama H., Ge H., Zhang Y. MIP-3alpha and MIP-1alpha rapidly mobilize dendritic cell precursors into the peripheral blood. J Leukoc Biol 2008, 84(6):1549-1556.
45. Ohno M., Hirata T., Enomoto M., Araki T., Ishimaru H., Takahashi T.A. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol Immunol 2000, 37(8):407-412.
46. Peng Q., Li K., Wang N., Li Q., Asgari E., Lu B., et al. Dendritic cell function in allostimulation is modulated by C5aR signaling. J Immunol 2009, 183(10):6058-6068.
47. Scott P., Trinchieri G. IL-12 as an adjuvant for cell-mediated immunity. Semin Immunol 1997, 9(5):285-291.
48. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol 2002, 23(9):445-449.
49. Jonuleit H., Schmitt E., Steinbrink K., Enk A.H. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001, 22(7):394-400.
50. Cho H.I., Celis E. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 2009, 69(23):9012-9019.
51. Zabaleta A., Arribillaga L., Llopiz D., Dotor J., Lasarte J.J., Prieto J., et al. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40. Antiviral Res 2007, 74(1):25-35.
52. Scola A.M., Johswich K.O., Morgan B.P., Klos A., Monk P.N. The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol 2009, 46(6):1149-1162.
53. Werling D., Hope J.C., Chaplin P., Collins R.A., Taylor G., Howard C.J. Involvement of caveolae in the uptake of respiratory syncytial virus antigen by dendritic cells. J Leukoc Biol 1999, 66(1):50-58.
54. Hirosue S., Kourtis I.C., van der Vlies A.J., Hubbell J.A., Swartz M.A. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation. Vaccine 2010, 28(50):7897-7906.
55. Win S.J., Ward V.K., Dunbar P.R., Young S.L., Baird M.A. Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunol Cell Biol 2011, 89(6):681-688.
56. Eglite S., Pluss K., Dahinden C.A. Requirements for C5a receptor-mediated IL-4 and IL-13 production and leukotriene C4 generation in human basophils. J Immunol 2000, 165(4):2183-2189.
57. Cain S.A., Monk P.N. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J Biol Chem 2002, 277(9):7165-7169.
58. Scola A.M., Higginbottom A., Partridge L.J., Reid R.C., Woodruff T., Taylor S.M., et al. The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding. J Biol Chem 2007, 282(6):3664-3671.
59. Martin-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004, 5(12):1260-1265.
60. Weaver D.J., Reis E.S., Pandey M.K., Kohl G., Harris N., Gerard C., et al. C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. Eur J Immunol 2010, 40(3):710-721.
61. Haas P.J., van Strijp J. Anaphylatoxins: their role in bacterial infection and inflammation. Immunol Res 2007, 37(3):161-175.
62. Toro K., Borka K., Kardos M., Kristof I., Sotonyi P. Expression and function of C5a receptor in a fatal anaphylaxis after honey bee sting. J Forensic Sci 2011, 56(2):526-528.